Overview

A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women

Status:
Completed
Trial end date:
2021-08-12
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to estimate the cumulative amount of lemborexant excreted in breast milk following a single dose administration of lemborexant 10 milligram (mg) to healthy lactating women and to estimate the relative infant dose (RID) expressed as a percent of the daily maternal dose.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Lemborexant